PMID- 26907936 OWN - NLM STAT- MEDLINE DCOM- 20161101 LR - 20210816 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 16 DP - 2016 Feb 22 TI - Prognostic value of ERBB4 expression in patients with triple negative breast cancer. PG - 138 LID - 10.1186/s12885-016-2195-3 [doi] LID - 138 AB - BACKGROUND: Triple-negative breast cancer (TNBC) is known for aggressive biologic features and poor prognosis. Epidermal growth factor receptor (EGFR) overexpression in TNBC indicates poor prognosis. However, there is no previous study of the relationship between expression of the entire human epidermal growth factor receptor (HER) family genes and patient prognosis in TNBC. Accordingly, we investigated the expression profiles of HER family genes in patients with TNBC to determine the prognostic value and clinical implications of HER family expression. METHODS: We used the nCounter expression assay (NanoString(R)) to measure the expression of EGFR, erb-B2 receptor tyrosine kinase 2 (ERBB2), ERBB3, ERBB4, and estrogen receptor 1 (ESR1) genes using mRNA extracted from paraffin-embedded tumor tissues from 203 patients diagnosed with TNBC. Our data were validated using a separate cohort of 84 TNBC patients. RESULTS: A total of 203 TNBC patients who received adjuvant chemotherapy after curative surgery from 2000 to 2004 formed the training set. The 84 TNBC patients in the validation consort were selected from breast cancer patients who received curative surgery since 2005 to 2010. Analysis of the expression profiles of the HER family genes in TNBC tissue specimens revealed that increased expression of ERBB4 was associated with poor prognosis according to survival analysis (5-year distant relapse free survival [5Y DRFS], low vs. high expression [cut-off: median]: 90.1% vs. 80.2%; p = 0.022). This trend was also observed in the validation set of TNBC patients (5Y DRFS, low vs. high: 69.4% vs. 44.7%; p = 0.053). In a multivariate Cox regression model, ERBB4 expression was identified as a indicator of long-term prognosis in patients with TNBC. CONCLUSIONS: The expression profile of ERBB4, a member of the HER family, might serve as a prognostic marker in patients with TNBC. FAU - Kim, Ji-Yeon AU - Kim JY AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. jyeon25.kim@samsung.com. FAU - Jung, Hae Hyun AU - Jung HH AD - Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. haehyun.jung@sbri.co.kr. FAU - Do, In-Gu AU - Do IG AD - Cancer of Companion Diagnostics, Innovative Cancer Medicine Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. ingu.do@samsung.com. FAU - Bae, SooYoun AU - Bae S AD - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. sooyoun.bae@samsung.com. FAU - Lee, Se Kyung AU - Lee SK AD - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. sekyung.lee@samsung.com. FAU - Kim, Seok Won AU - Kim SW AD - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. seokwon1.kim@samsung.com. FAU - Lee, Jeong Eon AU - Lee JE AD - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. jeongeon.lee@samsung.com. FAU - Nam, Seok Jin AU - Nam SJ AD - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. seokjin.nam@samsung.com. FAU - Ahn, Jin Seok AU - Ahn JS AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. jinseok.ahn@samsung.com. FAU - Park, Yeon Hee AU - Park YH AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. yhparkhmo@skku.edu. AD - Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. yhparkhmo@skku.edu. FAU - Im, Young-Hyuck AU - Im YH AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. imyh00@skku.edu. AD - Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea. imyh00@skku.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160222 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - 0 (Biomarkers, Tumor) RN - 0 (ESR1 protein, human) RN - 0 (Estrogen Receptor alpha) RN - EC 2.7.10.1 (EGFR protein, human) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.10.1 (ERBB3 protein, human) RN - EC 2.7.10.1 (ERBB4 protein, human) RN - EC 2.7.10.1 (ErbB Receptors) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - EC 2.7.10.1 (Receptor, ErbB-3) RN - EC 2.7.10.1 (Receptor, ErbB-4) SB - IM MH - Adult MH - Biomarkers, Tumor/*genetics MH - ErbB Receptors/genetics MH - Estrogen Receptor alpha/genetics MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Middle Aged MH - Prognosis MH - Receptor, ErbB-2/genetics MH - Receptor, ErbB-3/genetics MH - Receptor, ErbB-4/*genetics MH - Survival Analysis MH - Triple Negative Breast Neoplasms/drug therapy/*genetics/*pathology PMC - PMC4763414 EDAT- 2016/02/26 06:00 MHDA- 2016/11/02 06:00 PMCR- 2016/02/22 CRDT- 2016/02/25 06:00 PHST- 2015/09/03 00:00 [received] PHST- 2016/02/17 00:00 [accepted] PHST- 2016/02/25 06:00 [entrez] PHST- 2016/02/26 06:00 [pubmed] PHST- 2016/11/02 06:00 [medline] PHST- 2016/02/22 00:00 [pmc-release] AID - 10.1186/s12885-016-2195-3 [pii] AID - 2195 [pii] AID - 10.1186/s12885-016-2195-3 [doi] PST - epublish SO - BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3.